IBO · Impact Biomedical Inc. · Executive Compensation
$4.85
+0.01 (+0.21%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As reflected in the accompanying financial statements the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.”View the 10-Q filed Aug 7, 2026
Market Cap
$48.61M
Shares
8.54M
Volume · Oct 5
17.34K
Avg daily vol (9 sessions)
16.07K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark Suseck | Chief Operating Officer | $158,689 |
| Frank D. Heuszel | Chief Executive Officer | $54,806 |
| Todd D. Macko | Chief Financial Officer | $555 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Suseck | Chief Operating Officer | — |
| Todd D. Macko | Chief Financial Officer | — |
| Frank D. Heuszel | Chief Executive Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Chan Heng Fai Ambrose | Director | Appointed | 2025-03-13 |
| Jason T. Grady | Director | Appointed | 2024-06-07 |
| Heng Fai Ambrose Chan | member of the Board of Directors | Resigned | 2024-06-07 |